Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 44

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

A nanobody modulates the p53 transcriptional program without perturbing its functional architecture

Bethuyne, Jonas, De Gieter, Steven, Zwaenepoel, Olivier, Garcia-Pino, Abel, Durinck, Kaat, Verhelle, Adriaan, Hassanzadeh-Ghassabeh, Gholamreza, Speleman, Frank, Loris, Remy, Gettemans, Jan · 2014 · Nucleic Acids Research

Abstract

The p53 transcription factor plays an important role in genome integrity. To perform this task, p53 regulates the transcription of genes promoting various cellular outcomes including cell cycle arrest, apoptosis or senescence. The precise regulation of this activity remains elusive as numerous mechanisms, e.g. posttranslational modifications of p53 and (non-)covalent p53 binding partners, influence the p53 transcriptional program. We developed a novel, non-invasive tool to manipulate endogenous p53. Nanobodies (Nb), raised against the DNA-binding domain of p53, allow us to distinctively target both wild type and mutant p53 with great specificity. Nb3 preferentially binds 'structural' mutant p53, i.e. R175H and R282W, while a second but distinct nanobody, Nb139, binds both mutant and wild type p53. The co-crystal structure of the p53 DNA-binding domain in complex with Nb139 (1.9 Å resolution) reveals that Nb139 binds opposite the DNA-binding surface. Furthermore, we demonstrate that Nb139 does not disturb the functional architecture of the p53 DNA-binding domain using conformation-specific p53 antibody immunoprecipitations, glutaraldehyde crosslinking assays and chromatin immunoprecipitation. Functionally, the binding of Nb139 to p53 allows us to perturb the transactivation of p53 target genes. We propose that reduced recruitment of transcriptional co-activators or modulation of selected post-transcriptional modifications account for these observations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gku962

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 54

  1. Vousden, 2002, Live or let die: the cell's response to p53, Nat. Rev. Cancer, 2, 594, 10.1038/nrc864 · DOI · Paper page
  2. Joerger, 2008, Structural biology of the tumor suppressor p53, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
  3. Hainaut, 1998, IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools, Nucleic Acids Res., 26, 205, 10.1093/nar/26.1.205 · DOI · Paper page
  4. Ho, 2003, Transcriptional repression mediated by the p53 tumour suppressor, Cell Death Differ., 10, 404, 10.1038/sj.cdd.4401191 · DOI · Paper page
  5. Mihara, 2003, p53 has a direct apoptogenic role at the mitochondria, Mol. Cell, 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
  6. De Clercq, 2013, L-plastin nanobodies perturb matrix degradation, podosome formation, stability and lifetime in THP-1 macrophages, PloS One, 8, e78108, 10.1371/journal.pone.0078108 · DOI
  7. Van Audenhove, 2014, Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization, FASEB J., 28, 1805, 10.1096/fj.13-242537 · DOI
  8. Pruszynski, 2013, Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody, Nucl. Med. Biol., 40, 52, 10.1016/j.nucmedbio.2012.08.008 · DOI
  9. Van Impe, 2013, A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis, Breast Cancer Res., 15, R116, 10.1186/bcr3585 · DOI
  10. Baral, 2006, Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor, Nat. Med., 12, 580, 10.1038/nm1395 · DOI · Paper page
  11. VanOverbeke, 2014, Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model, Mol. Ther., 22, 1768, 10.1038/mt.2014.132 · DOI
  12. De Clercq, 2013, Nanobody-induced perturbation of LFA-1/L-plastin phosphorylation impairs MTOC docking, immune synapse formation and T cell activation, Cell. Mol. Life Sci., 70, 909, 10.1007/s00018-012-1169-0 · DOI
  13. Van den Abbeele, 2010, A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction, Cell. Mol. Life Sci., 67, 1519, 10.1007/s00018-010-0266-1 · DOI
  14. Bullock, 1997, Thermodynamic stability of wild-type and mutant p53 core domain, Proc. Natl Acad. Sci. U.S.A., 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
  15. Towbin, 1979, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications, Proc. Natl Acad. Sci. U.S.A., 76, 4350, 10.1073/pnas.76.9.4350 · DOI · Paper page
  16. Xu, 2011, Gain of function of mutant p53 by coaggregation with multiple tumor suppressors, Nat. Chem. Biol., 7, 285, 10.1038/nchembio.546 · DOI · Paper page
  17. Pattyn, 2006, RTPrimerDB: the real-time PCR primer and probe database, major update 2006, Nucleic Acids Res., 34, D684, 10.1093/nar/gkj155 · DOI
  18. Hellemans, 2007, qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data, Genome Biol., 8, R19, 10.1186/gb-2007-8-2-r19 · DOI · Paper page
  19. McPherson, 1982, Preparation and Analysis of Protein Crystals
  20. Kabsch, 2010, Integration, scaling, space-group assignment and post-refinement, Acta Crystallogr. A, 66, 133
  21. Winn, 2011, Overview of the CCP4 suite and current developments, Acta Crystallogr. D, 67, 235, 10.1107/S0907444910045749 · DOI · Paper page
  22. McCoy, 2007, Phaser crystallographic software, J. Appl. Crystallogr., 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
  23. Langer, 2008, Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7, Nat. Protoc., 3, 1171, 10.1038/nprot.2008.91 · DOI · Paper page
  24. Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr. D, 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
  25. Afonine, 2012, Towards automated crystallographic structure refinement with phenix.refine, Acta Crystallogr. D, 68, 352, 10.1107/S0907444912001308 · DOI · Paper page
  26. Chen, 2010, MolProbity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. D, 66, 12, 10.1107/S0907444909042073 · DOI · Paper page
  27. Hubbard, 1991, Molecular recognition. Conformational analysis of limited proteolytic sites and serine proteinase protein inhibitors, J. Mol. Biol., 220, 507, 10.1016/0022-2836(91)90027-4 · DOI · Paper page
  28. McDonald, 1994, Satisfying hydrogen bonding potential in proteins, J. Mol. Biol., 238, 777, 10.1006/jmbi.1994.1334 · DOI · Paper page
  29. Lee, 2006, Chromatin immunoprecipitation and microarray-based analysis of protein location, Nat. Protoc., 1, 729, 10.1038/nprot.2006.98 · DOI · Paper page
  30. Gevry, 2007, p21 transcription is regulated by differential localization of histone H2A.Z, Genes Dev., 21, 1869, 10.1101/gad.1545707 · DOI · Paper page
  31. Collavin, 2010, p53-family proteins and their regulators: hubs and spokes in tumor suppression, Cell Death Differ., 17, 901, 10.1038/cdd.2010.35 · DOI · Paper page
  32. Rothbauer, 2008, A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins, Mol. Cell. Proteomics, 7, 282, 10.1074/mcp.M700342-MCP200 · DOI · Paper page
  33. Nooren, 2003, Diversity of protein-protein interactions, EMBO J., 22, 3486, 10.1093/emboj/cdg359 · DOI · Paper page
  34. Perkins, 2010, Transient protein-protein interactions: structural, functional, and network properties, Structure, 18, 1233, 10.1016/j.str.2010.08.007 · DOI · Paper page
  35. Wang, 2007, Structure of the human p53 core domain in the absence of DNA, Acta Crystallogr. D, 63, 276, 10.1107/S0907444906048499 · DOI
  36. Ory, 1994, Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation, EMBO J., 13, 3496, 10.1002/j.1460-2075.1994.tb06656.x · DOI · Paper page
  37. Chen, 2010, Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer, Structure, 18, 246, 10.1016/j.str.2009.11.011 · DOI · Paper page
  38. Lane, 1992, Cancer. p53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
  39. Vousden, 2009, Blinded by the light: the growing complexity of p53, Cell, 137, 413, 10.1016/j.cell.2009.04.037 · DOI · Paper page
  40. Lozano, 2010, Mouse models of p53 functions, Cold Spring Harb. Perspect. Biol., 2, a001115, 10.1101/cshperspect.a001115 · DOI
  41. Berglind, 2008, Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination, Cancer Biol. Ther., 7, 699, 10.4161/cbt.7.5.5712 · DOI
  42. Berns, 2004, A large-scale RNAi screen in human cells identifies new components of the p53 pathway, Nature, 428, 431, 10.1038/nature02371 · DOI · Paper page
  43. Vassilev, 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
  44. Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
  45. Liu, 2013, Small molecule induced reactivation of mutant p53 in cancer cells, Nucleic Acids Res., 41, 6034, 10.1093/nar/gkt305 · DOI · Paper page
  46. Komarova, 2003, p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways, J. Biol. Chem., 278, 15465, 10.1074/jbc.C300011200 · DOI
  47. Rocha, 2003, The p53-inhibitor pifithrin-alpha inhibits firefly luciferase activity in vivo and in vitro, BMC Mol. Biol., 4, 9, 10.1186/1471-2199-4-9 · DOI
  48. Follis, 2014, The DNA-binding domain mediates both nuclear and cytosolic functions of p53, Nat. Struct. Mol. Biol., 21, 535, 10.1038/nsmb.2829 · DOI · Paper page
  49. Hagn, 2010, BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain, J. Biol. Chem., 285, 3439, 10.1074/jbc.M109.065391 · DOI
  50. Vaseva, 2009, The mitochondrial p53 pathway, Biochim. Biophys. Acta, 1787, 414, 10.1016/j.bbabio.2008.10.005 · DOI · Paper page
  51. Pardon, 2014, A general protocol for the generation of Nanobodies for structural biology, Nat. Protoc., 9, 674, 10.1038/nprot.2014.039 · DOI · Paper page
  52. Comel, 2014, The cytoplasmic side of p53's oncosuppressive activities, FEBS Lett., 588, 2600, 10.1016/j.febslet.2014.04.015 · DOI
  53. Delanote, 2010, An alpaca single-domain antibody blocks filopodia formation by obstructing L-plastin-mediated F-actin bundling, FASEB J., 24, 105, 10.1096/fj.09-134304 · DOI
  54. Oren, 2010, Mutant p53 gain-of-function in cancer, Cold Spring Harb. Perspect. Biol., 2, a001107, 10.1101/cshperspect.a001107 · DOI · Paper page

Cited by

Metadata

Authors
Bethuyne, J., De Gieter, S., Zwaenepoel, O., Garcia-Pino, A., Durinck, K., Verhelle, A., Hassanzadeh-Ghassabeh, G., Speleman, F., Loris, R., & Gettemans, J.
Venue
Nucleic Acids Research
Published
2014-10-16
Volume
42
Issue
20
Pages
12928-12938
ISSN
  • 1362-4962
  • 0305-1048
Cited by
44
References
10
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.